

Remarks

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 41-63 are pending in the application, with claim 41 being the independent claim. Claims 1-40 have been cancelled without prejudice to or disclaimer of the subject matter therein. Claims 41-63 have been added. It is believed these changes introduce no new matter, and their entry is respectfully requested.

Support for newly added claims 41-63 can be found throughout the specification. For the Examiner's convenience, **Table 1** (attached) sets out examples of locations where support for the new claims can be found in the present application and the earliest priority application.

Applicants have organized the independent claim to include two peptides having the same priority date to aid in examination. Thus, Applicants request examination of both peptides. Applicants note that, to the best of Applicants' knowledge, the peptides recited in claims 41-43 were first disclosed in Appl. No. 08/159,184, filed November 29, 1993, which was originally incorporated by reference into the present application.

New claims 41, 42, 44-46, and 49-63 read on the peptide elected in Applicants' Reply to Restriction Requirement filed on December 3, 2003.

The specification has been amended to perfect the claim for benefit and to update the application numbers of related applications. As this application was filed before November 29, 2000, the amendment of the claim for benefit is timely. 37 C.F.R. § 1.78 (a)(2)(ii)(C). MPEP § 201.11(E).

The specification has also been amended in the paragraph beginning at page 12, line 30 to state that CTL-inducing peptides of the invention can be less than about 15 residues in length. Support for this amendment can be found in priority Appl. No. 08/159,184 at page 4, lines 30-33. This application, as noted above, was originally incorporated by reference into the present application.

The specification has been amended to insert the Substitute Sequence Listing, submitted herewith, which has been changed to reflect the current claim for benefit. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same. In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

It is believed that the application is now in condition for examination. Early notice to this effect is respectfully requested.

Conclusion

Consideration of this Amendment is respectfully requested. Applicants respectfully submit that the application is in proper condition for allowance.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: 2/11/2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



Table 1- Example of Support for Claims

<u>Claim Language</u>	<u>This Application</u>	<u>08/159,184</u>
T helper peptide	p. 43, lines 20-28; p. 50, line 17 through p. 51, line 22	p. 19, line 15 through p. 20, line 2
Spacer or linker	p. 50, lines 22-30, p. 52, lines 16-27	p. 19, lines 21-32
Carrier	p. 42, lines 28-30; p. 43, lines 3-6	p. 24, lines 15-21, and lines 29-38
Lipid	p. 43, lines 10-13; p. 51, line 25 through p. 52, line 15	p. 20, lines 3-31
Fusion protein	p. 38, lines 12-18	p. 21, line 35 through p. 22, line 1
Liposome	p. 56, lines 1-17	p. 25, lines 3-28
Homopolymer/ heteropolymer	p. 42, lines 28-33	p. 26, lines 29-31
Less than about 15 residues in length	p. 12, lines 33-34, as amended herein	p. 4, lines 30-33
8, 9, 10, or 11 amino acids in length	p. 12, line 33 through page 13, line 1	p. 4, lines 30-33